Reference number : GC-2017-Q4-00854, amendment number : , agreement type : G, recipient legal name : Jardim, Armando (McGill University)|Jardim, Armando (Université McGill), recipient country : CA, recipient province : nan, recipient city : Quebec|Québec, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Immunoprecise Antibodies (IPA) is a Victoria, BC based company with expertise in development and_x000D_
production of murine and rabbit monoclonal antibodies (mAbs). To expand its competitive foot print in the_x000D_
antibody and recombinant protein production sector, IPA is exploring new strategies that will provide a more_x000D_
rapid turn around in the production of high quality therapeutic or research antibodies. In the production of_x000D_
polyclonal or monoclonal antibodies, one of the most time consuming steps is the immunization and boosting_x000D_
of host animals; which typically requires 50-60 days. To minimize this lag time IPA is interested in developing_x000D_
a new antibody production platform that circumvents the immunization step and will produced full length IgG_x000D_
antibodies that have the correct glycosylation patterns. Implementing this strategy will involve the development_x000D_
of an novel bicistronic vectors that will be used to create a surface display IgG library in the protozoan_x000D_
organism Leishmania. Clones expressing the an IgG antibody that recognizes an antigen of interest can easily_x000D_
be isolated using a biopanning approach. A major advantage for using Leishmania is that this organism has_x000D_
glycosylation patterns that closely resemble thos observed on human and rabbit IgG antibodies. This project_x000D_
will provide that proof of principle data require for the ultimate creation of a human IgG surface display library., program purpose french : Immunoprecise Antibodies (IPA) is a Victoria, BC based company with expertise in development and_x000D_
production of murine and rabbit monoclonal antibodies (mAbs). To expand its competitive foot print in the_x000D_
antibody and recombinant protein production sector, IPA is exploring new strategies that will provide a more_x000D_
rapid turn around in the production of high quality therapeutic or research antibodies. In the production of_x000D_
polyclonal or monoclonal antibodies, one of the most time consuming steps is the immunization and boosting_x000D_
of host animals; which typically requires 50-60 days. To minimize this lag time IPA is interested in developing_x000D_
a new antibody production platform that circumvents the immunization step and will produced full length IgG_x000D_
antibodies that have the correct glycosylation patterns. Implementing this strategy will involve the development_x000D_
of an novel bicistronic vectors that will be used to create a surface display IgG library in the protozoan_x000D_
organism Leishmania. Clones expressing the an IgG antibody that recognizes an antigen of interest can easily_x000D_
be isolated using a biopanning approach. A major advantage for using Leishmania is that this organism has_x000D_
glycosylation patterns that closely resemble thos observed on human and rabbit IgG antibodies. This project_x000D_
will provide that proof of principle data require for the ultimate creation of a human IgG surface display library., agreement title english : A Leishmania display platform for expression of human antibodies and glycoproteins, agreement title french : A Leishmania display platform for expression of human antibodies and glycoproteins, agreement number : EGP, agreement value : 25000.0, agreement start date : 2018-03-07, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada